

Jordana Kate Schmier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4627853/publications.pdf>

Version: 2024-02-01

97
papers

6,456
citations

117625

34
h-index

64796

79
g-index

97
all docs

97
docs citations

97
times ranked

7767
citing authors

#	ARTICLE	IF	CITATIONS
1	Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patientsâ€™ Perspectives on Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e185-e198.	0.4	9
2	Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.4	2
3	Cardiovascular Healthcare Cost Savings Associated with Increased Whole Grains Consumption among Adults in the United States. <i>Nutrients</i> , 2020, 12, 2323.	4.1	13
4	Health Care Costs and Savings Associated with Increased Dairy Consumption among Adults in the United States. <i>Nutrients</i> , 2020, 12, 233.	4.1	8
5	Health Economic Evaluation Modeling Shows Potential Health Care Cost Savings with Increased Conformance with Healthy Dietary Patterns among Adults in the United States. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2019, 119, 599-616.	0.8	30
6	A Systematic Review of Cost-Effectiveness Analyses of Left Ventricular Assist Devices: Issues and Challenges. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 35-46.	2.1	11
7	Methodological challenges to evaluating the health economic impact of nutritional interventions. <i>World Nutrition</i> , 2019, 10, 38-53.	0.3	0
8	Costâ€Effectiveness of Remote Cardiac Monitoring With the <sc>CardioMEMS</sc> Heart Failure System. <i>Clinical Cardiology</i> , 2017, 40, 430-436.	1.8	76
9	Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. <i>Clinical Therapeutics</i> , 2017, 39, 1600-1617.	2.5	27
10	Effect of battery longevity on costs and health outcomes associated with cardiac implantable electronic devices: a Markov model-based Monte Carlo simulation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 50, 149-158.	1.3	10
11	An updated estimate of costs of endophthalmitis following cataract surgery among Medicare patients: 2010–2014. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 2121-2127.	1.8	24
12	Treatment costs of cystoid macular edema among patients following cataract surgery. <i>Clinical Ophthalmology</i> , 2016, 10, 477.	1.8	27
13	Estimated hospital costs associated with preventable health care-associated infections if health care antiseptic products were unavailable. <i>ClinicoEconomics and Outcomes Research</i> , 2016, 8, 197.	1.9	35
14	A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States. <i>Journal of Medical Economics</i> , 2016, 19, 1003-1010.	2.1	6
15	Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges. <i>Pharmacoeconomics</i> , 2016, 34, 259-272.	3.3	11
16	A Markov Model-based Monte Carlo Simulation to Assess Variation in Financial Burden and Health Outcomes for Cardiac Implantable Electronic Devices Based on Device and Patient Characteristics. <i>Journal of Cardiac Failure</i> , 2015, 21, S61.	1.7	0
17	Cost Savings of Reduced Constipation Rates Attributed to Increased Dietary Fibre Intakes in Europe: A Decision-Analytic Model. <i>Journal of Pharmacy and Nutrition Sciences (discontinued)</i> , 2015, 5, 14-23.	0.4	5
18	Comparative cost effectiveness of Coflex® interlaminar stabilization versus instrumented posterolateral lumbar fusion for the treatment of lumbar spinal stenosis and spondylolisthesis. <i>ClinicoEconomics and Outcomes Research</i> , 2014, 6, 125.	1.9	22

#	ARTICLE	IF	CITATIONS
19	Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs. <i>Clinical Ophthalmology</i> , 2014, 8, 1097.	1.8	24
20	Perioperative outcomes, complications, and costs associated with lumbar spinal fusion in older patients with spinal stenosis and spondylolisthesis. <i>Neurosurgical Focus</i> , 2014, 36, E5.	2.3	60
21	Mortality, Cost, and Downstream Disease of Total Hip Arthroplasty Patients in the Medicare Population. <i>Journal of Arthroplasty</i> , 2014, 29, 242-246.	3.1	22
22	Cost savings of reduced constipation rates attributed to increased dietary fiber intakes: a decision-analytic model. <i>BMC Public Health</i> , 2014, 14, 374.	2.9	37
23	Complications, Mortality, and Costs for Outpatient and Short-Stay Total Knee Arthroplasty Patients in Comparison to Standard-Stay Patients. <i>Journal of Arthroplasty</i> , 2014, 29, 510-515.	3.1	245
24	Mortality, Cost, and Health Outcomes of Total Knee Arthroplasty in Medicare Patients. <i>Journal of Arthroplasty</i> , 2013, 28, 449-454.	3.1	36
25	The Burden of Influenza B: A Structured Literature Review. <i>American Journal of Public Health</i> , 2013, 103, e43-e51.	2.7	281
26	Economic Burden of Periprosthetic Joint Infection in the United States. <i>Journal of Arthroplasty</i> , 2012, 27, 61-65.e1.	3.1	1,365
27	Medical Service Encounters and Payments Associated with Topical Adjunctive Therapy Use of Timolol for Glaucoma. <i>Clinical Drug Investigation</i> , 2012, 32, 835-842.	2.2	5
28	Cost-Effectiveness Analysis of Treatments for Vertebral Compression Fractures. <i>Applied Health Economics and Health Policy</i> , 2012, 10, 273-284.	2.1	33
29	Patterns and Costs Associated With Progression of Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , 2012, 154, 675-681.e1.	3.3	23
30	National Revision Burden for Lumbar Total Disc Replacement in the United States. <i>Spine</i> , 2010, 35, 690-696.	2.0	24
31	Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs. <i>Clinical Ophthalmology</i> , 2010, 4, 1137.	1.8	16
32	First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results. <i>Clinical Ophthalmology</i> , 2010, 4, 437.	1.8	3
33	First-year treatment costs among new initiators of topical prostaglandin analog identified from November 2007 through April 2008. <i>Current Medical Research and Opinion</i> , 2010, 26, 2769-2777.	1.9	6
34	First-year treatment costs among new initiators of topical prostaglandin analogs. <i>Clinical Ophthalmology</i> , 2009, 3, 637.	1.8	10
35	Characteristics of respondents with glaucoma and dry eye in a national panel survey. <i>Clinical Ophthalmology</i> , 2009, 3, 645.	1.8	12
36	First-year treatment patterns among new initiators of topical prostaglandin analogs. <i>Current Medical Research and Opinion</i> , 2009, 25, 851-858.	1.9	21

#	ARTICLE	IF	CITATIONS
37	Primary and Revision Arthroplasty Surgery Caseloads in the United States from 1990 to 2004. Journal of Arthroplasty, 2009, 24, 195-203.	3.1	179
38	Single food focus dietary guidance: lessons learned from an economic analysis of egg consumption. Cost Effectiveness and Resource Allocation, 2009, 7, 7.	1.5	10
39	Impact of visual impairment on service and device use by individuals with diabetic retinopathy. Disability and Rehabilitation, 2009, 31, 659-665.	1.8	10
40	MEDICARE EXPENDITURES ASSOCIATED WITH DIABETES AND DIABETIC RETINOPATHY. Retina, 2009, 29, 199-206.	1.7	33
41	The impact of climate change and aeroallergens on children's health. Allergy and Asthma Proceedings, 2009, 30, 229-237.	2.2	26
42	Trends in Annual Medicare Expenditures for Glaucoma Surgical Procedures From 1997 to 2006. JAMA Ophthalmology, 2009, 127, 900.	2.4	34
43	Infection Burden for Hip and Knee Arthroplasty in the United States. Journal of Arthroplasty, 2008, 23, 984-991.	3.1	851
44	Benefits And Costs Of Immunizing Children Against Influenza At School: An Economic Analysis Based On A Large-Cluster Controlled Clinical Trial. Health Affairs, 2008, 27, w96-w104.	5.2	46
45	Mortality Following the Diagnosis of a Vertebral Compression Fracture in the Medicare Population. Journal of Bone and Joint Surgery - Series A, 2008, 90, 1479-1486.	3.0	207
46	Future Clinical and Economic Impact of Revision Total Hip and Knee Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2007, 89, 144-151.	3.0	464
47	EVALUATION OF COSTS FOR CYSTOID MACULAR EDEMA AMONG PATIENTS AFTER CATARACT SURGERY. Retina, 2007, 27, 621-628.	1.7	74
48	Impacts of a Smoking Cessation Benefit Among Employed Populations. Journal of Occupational and Environmental Medicine, 2007, 49, 11-21.	1.7	34
49	Evaluation of Medicare Costs of Endophthalmitis among Patients after Cataract Surgery. Ophthalmology, 2007, 114, 1094-1099.	5.2	31
50	The impact of inadequately controlled asthma in urban children on quality of life and productivity. Annals of Allergy, Asthma and Immunology, 2007, 98, 245-251.	1.0	104
51	Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management:a United States perspective. Current Medical Research and Opinion, 2007, 23, 2867-2875.	1.9	11
52	The Economic Implications of Glaucoma. Pharmacoeconomics, 2007, 25, 287-308.	3.3	59
53	Cost of ciprofloxacin/dexamethasone vs. amoxicillin/clavulanic acid for the treatment of acute otitis media in tympanostomy tube patients in the US. Journal of Medical Economics, 2007, 10, 501-514.	2.1	0
54	The Burden of Age-Related Macular Degeneration. Pharmacoeconomics, 2006, 24, 319-334.	3.3	34

#	ARTICLE	IF	CITATIONS
55	Impact of visual impairment on service and device use by individuals with age-related macular degeneration (AMD). <i>Disability and Rehabilitation</i> , 2006, 28, 1331-1338.	1.8	17
56	Validation of the Daily Living Tasks Dependent on Vision (DLTV) Questionnaire in a U.S. Population with Age-Related Macular Degeneration. <i>Ophthalmic Epidemiology</i> , 2006, 13, 137-143.	1.7	14
57	Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression. <i>Current Medical Research and Opinion</i> , 2006, 22, 1737-1743.	1.9	7
58	Economics and Reimbursement for Spine Technologies. , 2006, , 509-527.		0
59	IMPACT OF VISUAL IMPAIRMENT ON USE OF CAREGIVING BY INDIVIDUALS WITH AGE-RELATED MACULAR DEGENERATION. <i>Retina</i> , 2006, 26, 1056-1062.	1.7	68
60	Anemia, costs and mortality in chronic obstructive pulmonary disease. <i>Cost Effectiveness and Resource Allocation</i> , 2006, 4, 17.	1.5	53
61	Efficacy, tolerability, and parent reported outcomes for cefdinir vs. high-dose amoxicillin/clavulanate oral suspension for acute otitis media in young children. <i>Current Medical Research and Opinion</i> , 2006, 22, 1839-1847.	1.9	21
62	Response to Compliance With Hypertension Therapy: Why Standards Are Needed. <i>Hypertension</i> , 2006, 48, .	2.7	0
63	Recommendations for Evaluating Compliance and Persistence With Hypertension Therapy Using Retrospective Data. <i>Hypertension</i> , 2006, 47, 1039-1048.	2.7	161
64	Cost of obesity in the workplace. <i>Scandinavian Journal of Work, Environment and Health</i> , 2006, 32, 5-11.	3.4	118
65	Resource utilization and costs of age-related macular degeneration. <i>Health Care Financing Review</i> , 2006, 27, 37-47.	1.8	18
66	EVALUATION OF HEALTHCARE RESOURCE UTILIZATION (HRLU) AND COSTS OF ANEMIA AMONG CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS. <i>Chest</i> , 2005, 128, 257S.	0.8	74
67	The quality of life impact of acute exacerbations of chronic bronchitis (AECB): A literature review. <i>Quality of Life Research</i> , 2005, 14, 329-347.	3.1	46
68	Meta-analysis of bacterial resistance to macrolidesâ€”providing generalizable results: authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 434-435.	3.0	1
69	Costs and Outcomes of Extended-Release vs. Immediate-Release Clarithromycin for Lower Respiratory Tract Infections. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 217-223.	1.6	1
70	High prevalence of macrolide resistance: not in every country! [Comment on: Halpern et al. <i>J Antimicrob Chemother</i> 2005; 55: 748â€“57]. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 433-434.	3.0	2
71	A Stitch in Time: Improving Public Health Early Warning Systems for Extreme Weather Events. <i>Epidemiologic Reviews</i> , 2005, 27, 115-121.	3.5	87
72	Meta-analysis of bacterial resistance to macrolides. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 748-757.	3.0	28

#	ARTICLE	IF	CITATIONS
73	Practical applications of usability theory to electronic data collection for clinical trials. <i>Contemporary Clinical Trials</i> , 2005, 26, 376-385.	1.8	24
74	Effects of Inhaled Corticosteroids on Mortality and Hospitalisation in Elderly Asthma and Chronic Obstructive Pulmonary Disease Patients. <i>Drugs and Aging</i> , 2005, 22, 717-729.	2.7	8
75	Allergic Rhinitis: A Potential Cause of Increased Asthma Medication Use, Costs, and Morbidity. <i>Journal of Asthma</i> , 2004, 41, 117-126.	1.7	72
76	Patient recall and recall bias of health state and health status. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 159-163.	1.4	183
77	Impact of long-term inhaled corticosteroid therapy on bone mineral density: results of a meta-analysis. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 92, 201-207.	1.0	65
78	Development and validation of a disease-specific treatment satisfaction questionnaire for gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 907-915.	3.7	44
79	Development and validation of the treatment satisfaction questionnaire for GERD (TSQ-G). <i>Gastroenterology</i> , 2003, 124, A505-A506.	1.3	0
80	Reduction in Oral Corticosteroid Use with Mometasone Furoate Dry Powder Inhaler Improves Health-Related Quality of Life in Patients with Severe Persistent Asthma. <i>Journal of Asthma</i> , 2003, 40, 383-393.	1.7	18
81	The Breathlessness, Cough, and Sputum Scale. <i>Chest</i> , 2003, 124, 2182-2191.	0.8	104

82

#	ARTICLE	IF	CITATIONS
91	Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease. <i>Quality of Life Research</i> , 2000, 9, 819-827.	3.1	44
92	Cost Effectiveness of Acute Imipramine Therapy versus Two Imipramine Maintenance Treatment Regimens for Panic Disorder. <i>Pharmacoeconomics</i> , 2000, 18, 383-391.	3.3	9
93	A survey of standards and guidelines for cost-effectiveness analysis in health care*. <i>American Heart Journal</i> , 1999, 137, S53-S61.	2.7	14
94	The Impact of Asthma on Health-Related Quality of Life. <i>Journal of Asthma</i> , 1998, 35, 585-597.	1.7	61
95	The Complexity of Treatment Adherence in Adults with Asthma: Challenges and Opportunities. <i>Journal of Asthma</i> , 1998, 35, 455-472.	1.7	46
96	Health Care CBA and CEA from 1991 to 1996: An Updated Bibliography. <i>Medical Care</i> , 1998, 36, MS1-MS9.	2.4	102
97	Patient-, Caregiver-, and Eye Care Professional-reported Burden of Geographic Atrophy Secondary to Age-related Macular Degeneration. <i>American Journal of Ophthalmic Clinical Trials</i> , 0, 2, 1.	0.0	4